Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

30.75 -2.18 (-6.63%)

Streaming Delayed Price Updated: 11:07 AM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

December 04, 2024

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

November 12, 2024

From Beam Therapeutics

Via GlobeNewswire

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views ↗

November 06, 2024

Via Benzinga

Beam Therapeutics's Earnings: A Preview ↗

November 04, 2024

Via Benzinga

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

November 06, 2024

Via Benzinga

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial ↗

November 05, 2024

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency

Via Benzinga

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

November 05, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

November 05, 2024

From Beam Therapeutics

Via GlobeNewswire

Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗

September 11, 2024

Via Benzinga

A Closer Look at 5 Analyst Recommendations For Beam Therapeutics ↗

August 22, 2024

Via Benzinga

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

October 29, 2024

From Beam Therapeutics

Via GlobeNewswire

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating ↗

August 14, 2024

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...

Via Benzinga

3 Gene Editing Stocks with Potential to Transform Medicine ↗

August 09, 2024

Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.

Via InvestorPlace

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗

August 06, 2024

BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

August 06, 2024

From Beam Therapeutics

Via GlobeNewswire

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗

July 28, 2024

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

Via Benzinga

IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday ↗

July 25, 2024

Via Benzinga

Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗

July 24, 2024

On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.

Via Investor's Business Daily

Why Is Conn’s (CONN) Stock Down 36% Today? ↗

July 24, 2024

Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing.

Via InvestorPlace

Topics Bankruptcy

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 ↗

July 24, 2024

Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock.

Via InvestorPlace

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday ↗

July 23, 2024

Via Benzinga

3 Gene Editing Stocks Shaping the Future of Medicine ↗

July 22, 2024

Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions

Via InvestorPlace

Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast ↗

July 18, 2024

Via Benzinga

Beam Therapeutics Announces Transition of Chief Financial Officer

July 15, 2024

From Beam Therapeutics

Via GlobeNewswire

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗

July 09, 2024

Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.

Via InvestorPlace

3 Stocks With the Potential to 10X Your Money ↗

July 09, 2024

These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.

Via InvestorPlace

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗

July 04, 2024

Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.